| Proposal Number | | | Proposal Description | | | Vote Required for Approval | | | Effect of Abstentions | | | Effect of Broker Non-Votes | |
| 1 | | | Election of Directors | | | Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. The | | | None | | | None | |
| 2 | | | Non-binding advisory vote on the compensation of our named executive officers | | | The number of shares that cast a vote “For” the proposal must exceed the number of shares that cast a vote “Against” the proposal. | | | None | | | None | |
| 3 | | | |||||||||||
Ratification of the Audit Committee’s selection of Ernst & Young as the Company’s independent registered public accounting firm for the fiscal year ending December 31, | | | The number of shares that cast a vote “For” the proposal must exceed the number of shares that cast a vote “Against” the proposal. | | | None | | | None | |
Name | | | Age | | | Position(s) | | |||
Todd R. Patrick | | | | | 58 | | | | Chief Executive Officer, Director | |
| | | | | | | Director | | ||
Sarah J. Schlesinger, M.D.(2) | | | | | 61 | | | | Director | |
Joseph M. Patti, Ph.D.(2) | | | | | 56 | | | | Director | |
Odysseas D. Kostas, M.D. | | | | | 46 | | | | Director | |
Todd C. Peterson, Ph.D.(1) | | | | | | | | Director | | |
Robin C. Kramer | | | | | 55 | | | | Director | |
Name | | | Audit(1) | | | Compensation | | | Nominating and Corporate Governance | | |||||||||
Richard J. Bastiani, Ph.D. | | | | | | | | | | | | | | | | | X* | | |
Odysseas Kostas, M.D. | | | | | | ||||||||||||||
| | | | | | | | | | | X | | | ||||||
Todd R. Patrick | | | | | | | | | | | | | | | | | | | |
Joseph M. Patti, Ph.D. | | | | | | | | | | | X* | | | | | | X | | |
Sarah J. Schlesinger, M.D. | | | | | | | | | | | X | | | | | | | | |
Todd C. Peterson, Ph.D. | | | | | X | | | | | | | | | | | | | | |
Robin C. Kramer | | | | | X* | | | | | | | | | | | | | | |
| | | Fiscal Year Ended December 31, 2019 | | | Fiscal Year Ended December 31, 2018 | | ||||||
Audit Fees | | | | $ | 277,000 | | | | | $ | — | | |
Audit Related Fees | | | | | 94,000 | | | | | | — | | |
Tax Fees | | | | | — | | | | | | — | | |
All Other Fees | | | | | — | | | | | | — | | |
Total | | | | $ | 371,000 | | | | | $ | — | | |
| | | Fiscal Year Ended December 31,2020 | | | Fiscal Year Ended December 31, 2019 | | ||||||
Armata Pharmaceuticals, Inc. | | | | | | | | | | | | | |
Audit Fees | | | | $ | 362,000 | | | | | $ | 277,000 | | |
Audit Related Fees | | | | | 105,000 | | | | | | 94,000 | | |
Tax Fees | | | | | — | | | | | | — | | |
All Other Fees | | | | | — | | | | | | — | | |
Total | | | | $ | 467,000 | | | | | $ | 371,000 | | |
AmpliPhi Biosciences Corporation | | | | | | | | | | | | | |
Audit Fees | | | | $ | — | | | | | $ | 143,000 | | |
Audit Related Fees | | | | | — | | | | | | 102,000 | | |
Tax Fees | | | | | — | | | | | | — | | |
All Other Fees | | | | | — | | | | | | — | | |
Total | | | | $ | — | | | | | $ | 245,000 | | |
C3J Therapeutics, Inc. | | | | | | | | | | | | | |
Audit Fees | | | | $ | — | | | | | $ | 26,000 | | |
Audit Related Fees | | | | | — | | | | | | — | | |
Tax Fees | | | | | — | | | | | | — | | |
All Other Fees | | | | | — | | | | | | — | | |
Total | | | | $ | — | | | | | $ | 26,000 | | |
Grand total | | | | $ | 467,000 | | | | | $ | 642,000 | | |
| | | Fiscal Year Ended December 31, 2019 | | | Fiscal Year Ended December 31, 2018 | | ||||||
Audit Fees(1) | | | | $ | 143,000 | | | | | $ | 270,000 | | |
Audit Related Fees(2) | | | | | 102,000 | | | | | | 121,000 | | |
Tax Fees | | | | | — | | | | | | — | | |
All Other Fees | | | | | — | | | | | | — | | |
Total | | | | $ | 245,000 | | | | | $ | 391,000 | | |
| | | Fiscal Year Ended December 31, 2019 | | | Fiscal Year Ended December 31, 2018 | | ||||||
Audit Fees(1) | | | | $ | 26,000 | | | | | $ | 253,000 | | |
Audit Related Fees(2) | | | | | — | | | | | | 71,000 | | |
Tax Fees | | | | | — | | | | | | — | | |
All Other Fees | | | | | — | | | | | | — | | |
Total | | | | $ | 26,000 | | | | | $ | 324,000 | | |
Name | | | Age | | | Position(s) | | |||
Todd R. Patrick | | | | | 58 | | | | Chief Executive Officer & Director | |
Brian Varnum, Ph.D. | | | | 61 | | | | President & Chief Development Officer | | |
Steve R. Martin | | | | 60 | | | | Chief Financial Officer | | |
Duane Morris | | | | 71 | | | | Vice President, Operations | |
| | | Beneficial Ownership | | |||||||||
Beneficial Owner | | | Number of Shares | | | Percent of Total | | ||||||
Greater than 5% Stockholders | | | | | | | | | | | | | |
Innoviva, Inc. | | | | | 17,421,600(1) | | | | | | 63.7% | | |
Delta Dental of Wisconsin | | | | | 2,107,675(2) | | | | | | 11.3% | | |
Delta Dental Plan of Michigan, Inc. | | | | | 1,265,802(3) | | | | | | 6.8% | | |
Delta Dental of California | | | | | 990,643(4) | | | | | | 5.3% | | |
| | | | | | | | | | | % | | |
Directors, Director Nominees and Named Executive Officers | | | | | | | | | | | | | |
Richard J. Bastiani, Ph.D. (Director) | | | | | 28,390(5) | | | | | | * | | |
Jeremy Curnock Cook (Director) | | | | | 44,685(6) | | | | | | * | | |
H. Stewart Parker (Director) | | | | | 28,390(7) | | | | | | * | | |
Odysseas D. Kostas, M.D. (Director) | | | | | 17,421,600(13) | | | | | | 63.7% | | |
Sarah J. Schlesinger, M.D. (Director) | | | | | 17,421,600(13) | | | | | | 63.7% | | |
Joseph M. Patti, Ph.D. (Director) | | | | | 13,692(14) | | | | | | * | | |
Todd C. Peterson, Ph.D. (Director) | | | | | 13,692(15) | | | | | | * | | |
Todd R. Patrick (Chief Executive Officer and Director) | | | | | 334,823(8) | | | | | | 1.8% | | |
Brian Varnum, Ph. D. (President and Chief Development Officer) | | | | | 148,564(9) | | | | | | * | | |
Steve R. Martin (Chief Financial Officer) | | | | | 47,097(10) | | | | | | * | | |
Duane Morris (Vice President of Operations) | | | | | 52,213(11) | | | | | | * | | |
Robin C. Kramer (Director Nominee) | | | | | — | | | | | | * | | |
All current executive officers, director nominees and directors as a group (12 persons)(12) | | | | | 18,133,146 | | | | | | 65.3% | | |
| | | Beneficial Ownership | | |||||||||
Beneficial Owner | | | Number of Shares | | | Percent of Total | | ||||||
Greater than 5% Stockholders | | | | | | | | | | | | | |
Innoviva, Inc. and Innoviva Strategic Opportunities, LLC | | | | | 29,729,294(1) | | | | | | 74.7% | | |
Delta Dental of Wisconsin | | | | | 2,107,675(2) | | | | | | 8.5% | | |
Delta Dental Plan of Michigan, Inc. | | | | | 1,265,802(3) | | | | | | 5.1% | | |
Directors and Named Executive Officers | | | | | | | | | | | | | |
Richard J. Bastiani, Ph.D. (Director) | | | | | 42,081(4) | | | | | | *% | | |
Jules Haimovitz (Director) | | | | | 29,729,294(5) | | | | | | 74.7% | | |
Odysseas D. Kostas, M.D. (Director) | | | | | 29,742,986(6) | | | | | | 74.7% | | |
Robin C. Kramer (Director) | | | | | — | | | | | | *% | | |
Joseph M. Patti, Ph.D. (Director) | | | | | 27,383(7) | | | | | | *% | | |
Todd C. Peterson, Ph.D. (Director) | | | | | 13,692(8) | | | | | | *% | | |
Sarah J. Schlesinger, M.D. (Director) | | | | | 29,742,986(9) | | | | | | 74.7% | | |
Todd R. Patrick (Chief Executive Officer and Director) | | | | | 409,504(10) | | | | | | 1.6% | | |
Brian Varnum, Ph. D. (President and Chief Development Officer) | | | | | 223,245(11) | | | | | | *% | | |
Steve R. Martin (Chief Financial Officer) | | | | | 84,730(12) | | | | | | *% | | |
Duane Morris (Vice President of Operations) | | | | | 70,884(13) | | | | | | *% | | |
All current executive officers and directors as a group (11 persons) (14) | | | | | 30,628,197 | | | | | | 75.8% | | |
Plan Category | | | Number of securities to be issued upon Exercise of outstanding options, Warrants and rights | | | Weighted- average exercise price of outstanding options, warrants and rights | | | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a) | | |||||||||
| | | (a) | | | (b) | | | (c) | | |||||||||
Equity compensation plans approved by security holders | | | | | 1,668,926 | | | | | $ | 6.30 | | | | | | 138,814 | | |
Equity compensation plans not approved by security holders | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | | 1,668,926 | | | | | $ | 6.30 | | | | | | 138,814 | | |
Name and Principal Position | | | Year | | | Salary ($) | | | Bonus ($) | | | Option Awards ($)(1) | | | Non-Equity Incentive Plan Compensation ($) | | | All Other Compensation ($) | | | Total ($) | | |||||||||||||||||||||
Todd Patrick Chief Executive Officer | | | | | 2019 | | | | | | 412,000 | | | | | | — | | | | | | 714,556 | | | | | | 144,200 | | | | | | — | | | | | | 1,270,756 | | |
| | | 2018 | | | | | | 412,000 | | | | | | — | | | | | | — | | | | | | 206,000 | | | | | | — | | | | | | 618,000 | | | ||
Brian Varnum, Ph. D. President and Chief Development Officer | | | | | 2019 | | | | | | 320,000 | | | | | | — | | | | | | 714,556 | | | | | | 89,600 | | | | | | — | | | | | | 1,124,156 | | |
| | | 2018 | | | | | | 320,000 | | | | | | — | | | | | | — | | | | | | 128,000 | | | | | | — | | | | | | 448,000 | | | ||
Steve Martin Senior VP and Chief Financial Officer | �� | | | | 2019 | | | | | | 320,000 | | | | | | — | | | | | | 357,278 | | | | | | 89,600 | | | | | | — | | | | | | 766,878 | | |
| | | 2018 | | | | | | 320,000 | | | | | | — | | | | | | — | | | | | | 109,000 | | | | | | — | | | | | | 429,000 | | | ||
Paul C. Grint, M.D. Former Chief Executive Officer(2) | | | | | 2019 | | | | | | 170,928 | | | | | | — | | | | | | 4,125 | | | | | | — | | | | | | 519,717 | | | | | | 694,770 | | |
| | | 2018 | | | | | | 475,000 | | | | | | — | | | | | | — | | | | | | 143,000 | | | | | | — | | | | | | 618,000 | | |
Name and Principal Position | | | Year | | | Salary ($) | | | Bonus ($) | | | Option Awards ($)(1) | | | Non-Equity Incentive Plan Compensation ($) | | | All Other Compensation ($) | | | Total ($) | | |||||||||||||||||||||
Todd Patrick | | | | | 2020 | | | | | | 515,500 | | | | | | — | | | | | | 53,504 | | | | | | 257,750 | | | | | | — | | | | | | 826,754 | | |
Chief Executive Officer | | | | | 2019 | | | | | | 412,000 | | | | | | — | | | | | | 714,556 | | | | | | 144,200 | | | | | | — | | | | | | 1,270,756 | | |
Brian Varnum, Ph. D. | | | | | 2020 | | | | | | 398,750 | | | | | | — | | | | | | 53,504 | | | | | | 159,500 | | | | | | — | | | | | | 611,754 | | |
President and Chief Development Officer | | | | | 2019 | | | | | | 320,000 | | | | | | — | | | | | | 714,556 | | | | | | 89,600 | | | | | | — | | | | | | 1,124,156 | | |
Steve Martin | | | | | 2020 | | | | | | 350,000 | | | | | | — | | | | | | 53,504 | | | | | | 140,000 | | | | | | — | | | | | | 543,504 | | |
Senior VP and Chief Financial Officer | | | | | 2019 | | | | | | 320,000 | | | | | | — | | | | | | 357,278 | | | | | | 89,600 | | | | | | — | | | | | | 766,878 | | |
Name | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | ||||||||||||||||||||||||||||||||
Mr. Patrick | | | | 56,056(1) | | | | | — | | | | | 38.12 | | | | | 4/24/2024 | | | | | | 56,056(1) | | | | | — | | | | | 38.12 | | | | | 4/24/2024 | | | ||||||||
| | | | — | | | | | 298,724(2) | | | | | 3.15 | | | | | 5/21/2029 | | | | | | 74,681(2) | | | | | 224,043(2) | | | | | 3.15 | | | | | 5/21/2029 | | | ||||||||
| | | | 56,056 | | | | | 298,724 | | | | | | | | | | | | | | | | — | | | | | 23,000(5) | | | | | 3.15 | | | | | 12/7/2030 | | | ||||||||
| | | | 130,737 | | | | | 247,043 | | | | | | | | | | | | | |||||||||||||||||||||||||||||
Dr. Varnum | | | | 20,718(3) | | | | | — | | | | | 27.37 | | | | | 3/12/2022 | | | | | | 20,718(3) | | | | | — | | | | | 27.37 | | | | | 3/12/2022 | | | ||||||||
| | | | 986(1) | | | | | — | | | | | 33.05 | | | | | 6/25/2022 | | | |||||||||||||||||||||||||||||
| | | | 986(1) | | | | | — | | | | | 33.05 | | | | | 6/25/2022 | | | | | | 15,193(1) | | | | | — | | | | | 38.12 | | | | | 4/21/2024 | | | ||||||||
| | | | 15,193(1) | | | | | — | | | | | 38.12 | | | | | 4/21/2024 | | | | | | 4,932(1) | | | | | — | | | | | 38.12 | | | | | 12/8/2024 | | | ||||||||
| | | | 4,932(1) | | | | | — | | | | | 38.12 | | | | | 12/8/2024 | | | | | | 74,681(2) | | | | | 224,043(2) | | | | | 3.15 | | | | | 5/21/2029 | | | ||||||||
| | | | — | | | | | 298,724(2) | | | | | 3.15 | | | | | 5/21/2029 | | | | | | — | | | | | 23,000(5) | | | | | 3.15 | | | | | 12/7/2030 | | | ||||||||
| | | | 41,829 | | | | | 298,724 | | | | | | | | | | | | | | | | 116,510 | | | | | 247,043 | | | | | | | | | | | | | ||||||||
Mr. Martin | | | | 608(1) | | | | | 14(1) | | | | | 399.00 | | | | | 1/17/2026 | | | | | | 713(1) | | | | | — | | | | | 399.00 | | | | | 1/17/2026 | | | ||||||||
| | | | 1,152(4) | | | | | — | | | | | 60.20 | | | | | 3/31/2021 | | | | | | 1,152(4) | | | | | — | | | | | 60.20 | | | | | 3/31/2021 | | | ||||||||
| | | | 5,588(1) | | | | | 4,340(1) | | | | | 12.74 | | | | | 9/6/2027 | | | | | | 8,072(1) | | | | | 1,856(1) | | | | | 12.74 | | | | | 9/6/2027 | | | ||||||||
| | | | — | | | | | 149,362(2) | | | | | 3.15 | | | | | 5/21/2029 | | | | | | 37,341(2) | | | | | 112,021(2) | | | | | 3.15 | | | | | 5/21/2029 | | | ||||||||
| | | | 7,348 | | | | | 153,716 | | | | | | | | | | | | | | | | — | | | | | 23,000(5) | | | | | 3.15 | | | | | 12/7/2030 | | | ||||||||
Dr. Grint(6) | | | | 1,786(5) | | | | | —(1) | | | | | 3.15 | | | | | 11/6/2020 | | | |||||||||||||||||||||||||||||
| | | | 1,786 | | | | | — | | | | | | | | | | | | | | | | 47,278 | | | | | 136,877 | | | | | | | | | | | | |
Name | | | Fees Earned or Paid in Cash ($) | | | Option Awards ($)(1) | | | All Other Compensation ($) | | | Total ($) | | ||||||||||||
Richard Bastiani | | | | | 41,786 | | | | | | 63,249 | | | | | | — | | | | | | 105,035 | | |
Richard Bear(3) | | | | | 25,714 | | | | | | 63,249 | | | | | | — | | | | | | 88,963 | | |
H. Stewart Parker | | | | | 37,286 | | | | | | 63,249 | | | | | | — | | | | | | 100,535 | | |
Joseph Patti | | | | | 30,857 | | | | | | 63,249 | | | | | | — | | | | | | 94,106 | | |
Todd Peterson | | | | | 10,000 | | | | | | 75,714 | | | | | | — | | | | | | 85,714 | | |
Jeremy Curnock Cook | | | | | 57,786 | | | | | | 63,249 | | | | | | — | | | | | | 121,035 | | |
Louis Drapeau(2) | | | | | 22,500 | | | | | | — | | | | | | — | | | | | | 22,500 | | |
Michael S. Perry, Ph.D.(3) | | | | | 57,071 | | | | | | 63,249 | | | | | | — | | | | | | 120,320 | | |
Vijay Samant(2) | | | | | 16,429 | | | | | | — | | | | | | — | | | | | | 16,429 | | |
Wendy S. Johnson(2) | | | | | 14,286 | | | | | | — | | | | | | — | | | | | | 14,286 | | |
Name | | | Fees Earned or Paid in Cash ($) | | | Option Awards ($)(1) | | | All Other Compensation ($) | | | Total ($) | | ||||||||||||
Richard Bastiani | | | | | 74,750 | | | | | | 53,504 | | | | | | — | | | | | | 128,254 | | |
Odysseas Kostas | | | | | 38,572 | | | | | | 137,257 | | | | | | — | | | | | | 175,830 | | |
Robin C. Kramer | | | | | 3,677 | | | | | | 69,787 | | | | | | — | | | | | | 73,465 | | |
Joseph Patti | | | | | 54,282 | | | | | | 53,504 | | | | | | — | | | | | | 107,785 | | |
Todd Peterson | | | | | 46,339 | | | | | | 53,504 | | | | | | — | | | | | | 99,843 | | |
Sarah J. Schlesinger | | | | | 40,185 | | | | | | 137,257 | | | | | | — | | | | | | 177,443 | | |
Richard Bear(2) | | | | | 4,713 | | | | | | — | | | | | | — | | | | | | 4,713 | | |
Jeremy Curnock Cook(3) | | | | | 49,911 | | | | | | — | | | | | | — | | | | | | 49,911 | | |
H. Stewart Parker(3) | | | | | 59,231 | | | | | | — | | | | | | — | | | | | | 59,231 | | |
Michael S. Perry, Ph.D.(2) | | | | | 6,598 | | | | | | — | | | | | | — | | | | | | 6,598 | | |
Board of Directors: | | Stock Options Outstanding | | Stock Options Exercisable | | | Stock Options Outstanding | | Stock Options Exercisable | | ||||||||||||||||
Richard Bastiani | | | | 28,192 | | | | | 809 | | | | | | 51,192 | | | | | 14,501 | | | ||||
Richard Bear(3) | | | | 27,383 | | | | | — | | | |||||||||||||||
Jeremy Curnock Cook | | | | 28,497 | | | | | 1,108 | | | |||||||||||||||
H. Stewart Parker | | | | 28,192 | | | | | 809 | | | |||||||||||||||
Odysseas Kostas | | | | 50,383 | | | | | — | | | |||||||||||||||
Robin C. Kramer | | | | 30,000 | | | | | — | | | |||||||||||||||
Joseph Patti | | | | 50,383 | | | | | 13,692 | | | |||||||||||||||
Todd Peterson | | | | 27,383 | | | | | — | | | | | | 50,383 | | | | | 13,692 | | | ||||
Michael Perry(3) | | | | 28,275 | | | | | 847 | | | |||||||||||||||
Joseph Patti | | | | 27,383 | | | | | — | | | |||||||||||||||
Sarah J. Schlesinger | | | | 50,383 | | | | | — | | | |||||||||||||||
Richard Bear(2) | | | | — | | | | | — | | | |||||||||||||||
Jeremy Curnock Cook(3) | | | | 14,800 | | | | | 14,800 | | | |||||||||||||||
H. Stewart Parker(3) | | | | 14,501 | | | | | 14,501 | | | |||||||||||||||
Michael S. Perry, Ph.D.(2) | | | | — | | | | | — | | |